Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSP-CAR30 in relapsed or refractory CD30-positive Hodgkin and T-cell lymphoma
2024-515624-36-00Phase 2Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Dec 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous CD30.CAR-T in classical Hodgkin lymphoma (cHL), T-cell lymphoma, anaplastic large cell lymphoma (ALCL) and 1 more, sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoints: Dose-limiting toxicity, Safety and 1 more. Planned start Dec 2024; status: authorised.
02
Drugs
autologous CD30.CAR-T
03
Conditions
classical Hodgkin lymphoma (cHL)T-cell lymphomaanaplastic large cell lymphoma (ALCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2024-515624-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515624-36-00.